OSTEOGENIC CELL THERAPY FOR BONE REGENERATION

用于骨再生的成骨细胞疗法

• 批准号: 2790182
• 负责人: SUDHAKAR KADIYALA
• 金额: $ 10万
• 依托单位: OSIRIS THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-06-01 至 2000-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2790182
• 关键词: athymic mouse; bone regeneration; cell transplantation; connective tissue disorder; human tissue; laboratory rat; mesenchyme; osteogenesis; skeletal disorder; stem cells; tissue /cell culture; tissue engineering

In the context of skeletal tissue repair, Regenerative Medicine (TM) is the local application of adult stem cells to promote reconstruction of tissue defects. The objective of Regenerative Medicine (TM) is to deliver a high density of repair-competent cells to the defect site in a format that optimizes both the initial healing process and the subsequent tissue integration and remodeling. Osiris Therapeutics, Inc. is engaged in the development of cellular transplants and cell-matrix products for the treatment of connective tissue disorders. These cellular transplants and cell- matrix products are derived from Mesenchymal Stem Cells (MSCs), the progenitor cells that give rise to all mesenchymal tissues such as bone, cartilage, tendon, muscle, fat and bone marrow. Previous pre-clinical animal studies by Osiris scientists have established the efficacy of autologous MSCs to heal large bone defects. In the current proposal, we intend to test whether by using MSCs that have been pre-directed into the osteogenic lineage, we can optimize the regenerative process to accelerate and enhance bone formation over that achieved by implantation of undifferentiated MSCs. This Phase I proposal is designed to determine the parameters governing osteogenic human MSC-based implants that lead to the optimal regeneration of clinically significant bone defects. PROPOSED COMMERCIAL APPLICATION: The development of a commercially available cell-based bone graft substitute, with enhanced and accelerated healing potential, will have a beneficial impact on the treatment of patients requiring bone augmentation of clinical settings such as a spine fusion, treatment of non-unions and cysts, prosthetic implant fixation, and craniofacial reconstruction.

在骨骼组织修复的背景下，再生医学（TM）是成人干细胞的局部应用，以促进组织缺损的重建。再生医学（TM）的目标是以一种优化初始愈合过程和随后的组织整合和重塑的形式将高密度的修复能力细胞输送到缺损部位。Osiris Therapeutics，Inc.从事治疗结缔组织疾病的细胞移植和细胞基质产品的开发。这些细胞移植物和细胞基质产物来源于间充质干细胞（MSC），即产生所有间充质组织如骨、软骨、肌腱、肌肉、脂肪和骨髓的祖细胞。Osiris科学家先前的临床前动物研究已经确定了自体MSC治愈大骨缺损的功效。在目前的提案中，我们打算测试是否通过使用已预定向成骨谱系的MSC，我们可以优化再生过程，以加速和增强骨形成，而不是通过植入未分化的MSC来实现。该I期提案旨在确定用于指导成骨人类MSC基植入物的参数，这些参数可导致临床显著骨缺损的最佳再生。拟定商业应用：市售细胞基骨移植替代物的开发具有增强和加速愈合的潜力，将对需要临床骨增强的患者的治疗产生有益影响，例如脊柱融合、骨不连和囊肿的治疗、假体植入物固定和颅面重建。